up
complex
system
compos
multipl
molecular
machineri
act
synchron
manner
maintain
dynam
equilibrium
compon
up
often
repres
two
group
separ
molecular
mechan
first
group
compris
specif
enzym
cofactor
act
modifydemodifi
protein
substrat
singl
member
ubiquitin
famili
second
group
up
proteasom
approxim
kda
respons
proteolysi
label
substrat
ubiquitin
famili
protein
modifi
also
known
ubiquitinlik
modifi
ubl
compos
least
member
share
modest
primari
sequenc
ident
ubiquitin
preserv
compact
globular
fold
hochstrass
mammalian
famili
includ
small
ubiquitinlik
modifi
sumo
neuron
precursor
cellexpress
development
downregul
also
known
yeast
ubiquitin
crossreact
protein
ucrp
altern
name
interferonstimul
ubiquitinrel
human
leukocyt
antigen
fassoci
fau
ubiquitinlik
protein
mub
membraneanchor
ubl
ubiquitin
ubiquitinlik
homolog
yeast
autophagi
protein
ubiquitin
member
ubiquitin
famili
attach
protein
substrat
biochem
process
similar
implic
distinct
set
enzym
capac
act
limit
number
reaction
fig
protein
modifi
ubiquitin
famili
gener
proteolyt
cleavag
higher
molecular
weight
precursor
expos
doubl
glycin
gg
signatur
typic
found
famili
requir
attach
protein
substrat
review
jentsch
pyrowolaki
attach
conjug
ubiquitin
ubl
modifi
mediat
thiolest
cascad
reaction
requir
action
three
enzym
activ
enzym
activ
molecul
requir
reaction
conjug
enzym
case
conjug
protein
modifi
target
ubiquitin
ligas
respons
requir
achiev
conjug
modifi
target
protein
fig
role
exert
depend
capac
form
thiolest
intermedi
protein
modifi
ubiquitin
ligas
hect
famili
typic
exampl
activ
enzym
anoth
categori
ligas
contribut
bring
togeth
substrat
order
achiev
protein
conjug
without
enzymat
activ
among
categori
found
cullinr
ligas
crl
compos
multipl
subunit
allow
specif
recognit
degrad
substrat
eg
phosphoryl
contribut
factor
favour
chain
extens
also
propos
hopp
chain
format
essenti
drive
distinct
function
ubiquitin
chain
linkag
associ
degrad
chain
appear
connect
signal
cascad
endocyt
traffick
dna
repair
format
hybrid
chain
contain
ubiquitin
ubl
also
possibl
aillet
et
al
guzzo
matuni
kulathu
komand
gener
function
chain
establish
deubiquityl
enzym
dub
recogn
specif
ubiquitin
chain
target
substrat
ubiquitin
bind
domain
ubd
know
chain
cleav
eletr
wilkinson
equival
reaction
achiev
sumospecif
proteas
susp
specif
proteas
also
known
denedylas
hickey
et
al
isopeptidas
show
specif
modifi
howev
due
satur
vitro
assay
overexpress
certain
stress
condit
crossreact
report
thu
make
conclus
exclus
reaction
difficult
although
initi
drug
discoveri
strategi
use
enzym
recogn
protein
substrat
isopeptidas
develop
new
chemic
inhibitor
nowaday
enzym
consid
good
candid
drug
develop
proteasom
multisubunit
complex
form
barrelshap
proteolyt
core
core
particl
one
two
regulatori
particl
flank
end
core
regul
entri
protein
target
degrad
fig
bedford
et
al
core
particl
consist
four
stack
heptamer
ring
structur
compos
two
differ
type
subunit
two
outer
ring
form
seven
alpha
subunit
allow
interact
particl
inner
ring
compos
seven
beta
subunit
three
respons
catalyt
activ
catalyt
mechan
subunit
use
hydroxyl
group
ntermin
threonin
matur
perform
nucleophil
attack
carbonyl
carbon
peptid
bond
borissenko
groll
kisselev
goldberg
kisselev
et
al
voge
et
al
subunit
react
specif
substrat
subunit
possess
peptidylglutamyl
peptidehydrolyz
phgh
activ
cleav
acid
residu
trypsinlik
activ
cleav
basic
residu
subunit
show
chymotrypsinlik
activ
cleav
hydrophob
residu
sitedirect
mutagenesi
studi
catalyt
residu
yeast
show
drastic
chang
occur
subunit
inactiv
heinemey
et
al
divid
two
subparticl
base
lid
lid
contain
least
nine
nonatpas
polypeptid
chain
remov
polyubiquitin
chain
proteinsubstr
base
consist
four
nonatpas
six
atpas
subunit
interact
directli
atpas
control
open
gate
normal
lock
unfold
substrat
recogn
unfold
step
involv
atp
hydrolysi
peth
et
al
apart
proteasom
immunoproteasom
exist
immun
cell
subunit
also
known
reg
replac
subunit
dominantli
express
hematopoiet
cell
respons
proinflammatori
signal
interferon
gamma
cytokin
involv
antigen
process
subsequ
present
mhci
cell
surfac
allow
initi
immun
cell
respons
rock
et
al
tanaka
kasahara
furthermor
immuneproteasom
facilit
clearanc
protein
aggreg
prevent
cell
death
produc
ifninduc
oxid
stress
seifert
et
al
proteasom
inhibitor
current
use
clinic
trial
block
enzymat
activ
proteasom
howev
next
gener
proteasom
inhibitor
block
mechan
gate
open
regulatori
subunit
new
gener
proteasom
inhibitor
alway
aim
increas
potenc
specif
stabil
good
bioavail
pharmacokinet
convent
proteasom
inhibitor
effici
block
least
one
three
proteasom
activ
site
either
coval
noncoval
revers
irrevers
bind
inhibitor
drug
clinic
trial
mimet
peptid
interact
directli
activ
site
thu
block
nucleophil
attack
hydroxyl
group
proteasom
ntermin
threonin
activ
site
kisselev
goldberg
orlowski
kuhn
proteasom
inhibitor
often
classifi
accord
function
group
tabl
boron
acid
peptid
peptid
aldehyd
analogu
synthet
substitut
aldehyd
group
boron
acid
bortezomib
adam
et
al
bortezomib
potent
stabl
interact
specif
subunit
form
tetrahedr
intermedi
two
extra
hydrogen
bond
stabil
coval
bond
groll
et
al
bortezomib
revers
inhibitor
administr
intraven
low
dissoci
rate
behav
irrevers
molecul
dose
limit
toxic
produc
multipl
side
effect
patient
includ
pain
fatigu
gastrointestin
cardiovascular
pulmonari
disord
neutropenia
thrombocytopenia
peripher
neuropathi
despit
potenc
effect
treat
patient
develop
resist
bortezomib
year
treatment
mujtaba
et
al
resist
mechan
still
poorli
understood
multifactori
basi
xolalpa
et
al
secondgener
proteasom
inhibitor
current
clinic
trial
includ
boron
acid
peptid
unlik
bortezomib
inhibitor
reduc
neuropathi
oral
analogu
revers
inhibitor
phase
iii
trial
stronger
chymotrypsinlik
activ
inhibit
vivo
faster
dissoci
rate
abl
penetr
insid
tissu
kupperman
et
al
oral
inhibitor
phase
ii
trial
show
encourag
result
treatment
haematolog
solid
tumour
piva
et
al
epoxyketon
peptid
peptid
potent
specif
proteasom
inhibitor
known
form
morpholin
adduct
ntermin
threonin
coval
irrevers
bond
groll
et
al
carfilzomib
demo
et
al
chauhan
et
al
belong
class
inhibitor
show
high
chemic
stabil
caus
stronger
inhibit
chymotrypsinlik
proteasom
activ
bortezomib
huber
groll
overcom
problem
resist
bortezomib
due
higher
specif
neurotox
reduc
molineaux
side
effect
still
persist
fostier
et
al
carfilzomib
current
use
relaps
refractori
multipl
myeloma
oral
bioavail
includ
phase
ii
trial
shown
improv
therapeut
lacton
nonpeptid
inhibitor
also
develop
improv
bioavail
compound
deriv
marin
microorgan
salinispora
tropica
marizomib
inhibitor
phase
trial
fenic
et
al
group
react
catalyt
threonin
proteasom
activ
site
form
acylest
adduct
tetrahydrofuran
ring
stabil
bind
lead
highli
potent
select
oral
bioactiv
proteasom
inhibitor
contrari
epoxyketon
peptid
boron
acid
marizomib
inhibit
three
activ
proteasom
irrevers
stronger
longerlast
way
miller
et
al
use
marizomib
result
advers
effect
fatigu
nausea
vomit
dyspnea
second
gener
proteasom
inhibitor
design
specif
inhibit
subunit
interest
reduc
toxic
normal
cell
increas
apoptosi
tumour
cell
parlati
et
al
case
show
better
inhibit
chymotrypsinlik
improv
safeti
profil
compar
carfilzomib
epoxyketon
onx
onx
potent
drug
oral
bioavail
immunoproteasom
develop
treatment
autoimmun
disord
moreov
natur
product
noncoval
proteasom
inhibitor
also
develop
reduc
side
effect
timosaponin
aiii
exampl
natur
product
preclin
develop
whose
phase
iii
breast
cancer
prepar
withaferin
gambon
acid
natur
inhibitor
approv
chines
fda
cancer
clinic
trial
avoid
resist
proteasom
inhibitor
limit
offtarget
effect
develop
compound
act
noncompetit
way
directli
interact
activ
catalyt
subunit
site
consid
compound
could
potenti
use
combin
bortezomib
improv
clinic
outcom
exampl
rapamicin
compound
bind
subunit
therebi
produc
disrupt
interact
regulatori
subunit
block
entri
substrat
gaczynska
et
al
also
interact
insid
proteolyt
chamber
cytotox
myeloma
leukemia
cell
vitro
also
shown
decreas
tumour
size
xenograft
tumour
growth
vivo
li
et
al
overcom
resist
bortezomib
cultur
cell
line
proteasom
inhibitor
success
cancer
cell
high
prolif
rate
although
mechan
fulli
understood
seem
block
degrad
proapoptot
protein
cell
cycl
regul
fig
among
tumor
suppressor
retinoblastom
rb
cyclindepend
kinas
inhibitor
cdki
degrad
proteasom
franklandsearbi
bhaumik
rastogi
mishra
vlachostergio
et
al
regul
intrins
apoptot
pathway
also
control
proteasom
includ
member
protein
famili
proapoptot
protein
bax
bid
noxa
bad
antiapoptot
member
bclxl
bortezomib
treatment
increas
express
proapoptot
member
bax
smac
noxa
antiapoptot
protein
like
iap
downregul
thu
favor
apoptosi
tumor
cell
crawford
nahta
mechan
induc
apoptosi
proteasom
inhibitor
seem
differ
thu
combin
result
synergi
exampl
carfilzomib
marizomib
induc
apoptosi
mediat
caspas
better
bortezomib
depend
bax
bak
mitochondrionmedi
cell
death
kuhn
et
al
miller
et
al
inhibit
bortezomib
seem
import
role
drug
mechan
action
although
explain
anticanc
effect
fig
transcript
play
crucial
role
tumorigenesi
control
among
other
immun
inflammatori
respons
apoptosi
suppress
induc
antiapoptot
iap
bclxl
protein
angiogenesi
promot
induc
vascular
endotheli
growth
factor
vegf
favour
cell
prolifer
increas
cyclin
increas
cell
migrat
induc
metalloproteas
roccaro
et
al
furthermor
constitut
express
relat
resist
radiat
chemotherapi
variou
type
cancer
sunwoo
et
al
disrupt
proteasom
activ
also
lead
aggreg
unfold
protein
therebi
produc
er
stress
extens
protein
product
secret
found
differ
type
cancer
becom
sensit
er
stress
hoeller
dikic
er
stress
lead
upregul
endoribonucleasekinas
transcript
factor
increas
transcript
activ
proapoptot
noxa
armstrong
et
al
autophagi
also
induc
er
stress
resist
mechan
escap
cell
death
induc
pathway
activ
pathway
proteasom
stabil
inhibit
mtor
reduc
proteasom
degrad
belloni
et
al
activ
mapk
cjun
ntermin
kinas
also
report
proteasom
inhibit
lead
phosphoryl
consequ
cytochrom
c
releas
gener
reactiv
oxygen
speci
ro
treatment
proteasom
inhibitor
result
express
apoptosisrel
protein
fan
et
al
ro
respons
dna
damag
proteasom
play
crucial
role
dna
repair
activ
pathway
bortezomib
shown
promis
activ
durabl
respons
singl
agent
relaps
refractori
mcl
mm
patient
tabl
trial
phase
demonstr
effect
plateau
proteasom
inhibit
fair
toler
level
phase
ii
patient
refractori
mm
patient
pretreat
mcl
respond
bortezomib
therefor
fda
initi
approv
relapsedrefractori
mm
subsequ
relapsedrefractori
mcl
kane
et
al
moreov
surviv
rate
refractori
mm
patient
use
bortezomib
phase
iii
trial
exceed
respons
rate
patient
treat
previou
drug
choic
dexamethason
result
bortezomib
approv
firstlin
therapi
richardson
et
al
howev
refractori
respons
bortezomib
depend
tumour
cell
type
pancreat
prostat
nonsmal
lung
tumour
cell
sensit
diffus
larg
b
cell
lymphoma
follicular
lymphoma
waldenstrom
macroglobulinemia
solid
tumour
sarcoma
renal
cell
carcinoma
glioma
provid
slight
short
respons
franklandsearbi
bhaumik
overcom
bortezomib
resist
numer
combin
chemotherapeut
agent
immunomodul
andor
proteasom
inhibitor
investig
fda
approv
use
bortezomibdoxorubicin
combin
sinc
better
use
singl
compound
phase
iii
trial
combin
doxorubicinadriamycin
adr
thalidomid
melphalan
dexamethason
cyclophosphamid
myriad
also
success
activ
combin
date
includ
bortezomib
lenalidomid
dexamethason
overal
respons
obtain
phase
ii
earli
phase
ii
clinic
trial
use
combin
bortezomib
new
immunomodul
radioimmunotherapi
stem
cell
transplant
monoclon
antibodi
chemotherapeut
agent
promis
addit
target
therapi
histon
deacetylas
inhibitor
inhibitor
rapamycin
inhibitor
multipl
kinas
inhibitor
akt
pkc
cdk
inhibitor
etc
heat
shock
protein
inhibitor
simultan
use
bortezomib
also
show
encourag
result
mcbride
ryan
show
synergist
effect
associ
bortezomib
vorinostat
lenalodomid
dexamethason
refractori
mm
phase
iii
first
line
mm
patient
phase
iii
mcbride
ryan
studi
phase
iii
carfilzomib
exhibit
durabl
respons
accept
toxic
relapsedrefractori
mm
patient
compar
bortezomib
stem
cell
transplant
achiev
partial
respons
heavili
pretreat
patient
mcbride
ryan
pautasso
et
al
sever
phase
ii
trial
current
ongo
haematolog
malign
solid
tumour
phase
iii
trial
differ
compound
combin
includ
calfizomibthalidomidedexamethasonecyclosporamid
also
test
frontlin
treatment
mm
show
promis
activ
high
respons
rate
first
patient
evalu
last
proteasom
inhibitor
enter
phase
clinic
trial
marizomib
use
alon
combin
dexamethason
treatment
differ
kind
cancer
see
tabl
preclin
trial
marizomib
also
combin
bortezomib
sinc
differ
mechan
action
suggest
mcbride
ryan
mani
crl
substrat
tumour
suppressor
activ
prevent
degrad
protein
could
effect
anticanc
strategi
may
also
help
reduc
toxic
result
global
proteasom
inhibit
nawrocki
et
al
potent
select
firstinclass
small
molecul
inhibitor
develop
millennium
pharmaceut
report
specif
inhibitor
protein
neddyl
inactiv
heterodim
also
known
activ
enzym
nae
souci
et
al
wang
et
al
adenosin
sulpham
form
coval
adduct
bound
nae
activ
site
way
inhibit
format
thioester
adduct
mimic
situ
first
intermedi
nae
reaction
cycl
enzymat
process
brownel
et
al
nawrocki
et
al
inhibit
crl
activ
stabil
substrat
block
nae
subsequ
implic
cancer
cell
growth
surviv
bedford
et
al
first
report
potent
growth
suppressor
agent
varieti
cancer
cell
line
deriv
solid
tumour
haematolog
malign
vitro
vivo
xenograft
model
souci
et
al
zhao
et
al
preclin
trial
tumour
regress
occur
action
differ
mechan
depend
context
cell
type
induct
apoptosi
one
report
effect
mediat
three
differ
mechan
mainli
caus
accumul
stabil
crl
substrat
like
trigger
dna
rerepl
phase
arrest
block
activ
proapoptot
noxa
addit
apoptosi
also
induc
autophagi
concentr
timedepend
manner
multipl
human
cancer
cell
line
deriv
carcinoma
breast
colon
liver
brain
cervix
studi
reveal
autophagi
mainli
caus
inactiv
like
mediat
accumul
deptor
follow
activ
axi
studi
also
shown
induc
irrevers
senesc
multipl
cancer
cell
line
manner
cell
accumul
may
also
contribut
senesc
furthermor
potenti
sensit
role
chemotherapi
radiat
involv
mechanist
accumul
cjun
noxa
also
affect
promot
cflip
degrad
increas
express
killer
bik
inactiv
well
suppress
monoubiquityl
phosphoryl
result
gener
increas
cellular
sensit
enhanc
dna
damag
oxid
stress
cell
cycl
arrest
final
apoptosi
zhao
et
al
despit
promis
optim
strategi
inhibit
nae
pathway
recent
identifi
cancer
cell
develop
resist
treatment
resist
link
heterozyg
mutat
two
area
atp
bind
pocket
alanin
variou
residu
within
close
cleft
point
mutat
residu
reduc
affin
atp
interestingli
resist
effect
bypass
use
compound
tighter
bind
properti
nae
find
provid
critic
clinic
aspect
respect
patient
select
consolid
effort
develop
nextgener
nae
inhibitor
order
overcom
emerg
mutat
milhollen
et
al
toth
et
al
fact
use
virtual
screen
approach
natur
product
identifi
propos
second
inhibitor
nae
leung
et
al
cyclometal
rhodium
iii
complex
report
first
metal
complex
suppress
neddyl
pathway
via
inhibit
nae
occupi
bind
pocket
zhong
et
al
parallel
promis
result
preclin
model
includ
clinic
trial
cancer
therapi
sinc
see
tabl
total
seven
phase
iii
clinic
trial
patient
leukaemia
lymphoma
melanoma
sever
solid
tumour
trial
mainli
design
assess
safeti
discomfort
risk
inhibitor
establish
maximum
toler
dose
mtd
given
patient
describ
pharmacokinet
pk
paramet
pharmacodynam
pd
effect
evalu
diseas
respons
studi
combin
standard
treatment
gener
patient
receiv
escal
dose
administr
via
intraven
infus
differ
daili
schedul
pharmacokinet
measur
serial
blood
sampl
bone
marrow
aspir
bma
skin
punch
biopsi
fineneedl
tumour
biopsi
collect
follow
drug
dose
sampl
analys
measur
coval
adduct
express
crl
substrat
biomark
indic
nae
inhibit
peripher
tumour
tissu
zhao
et
al
pk
profil
similar
follow
dose
differ
day
suggest
appar
accumul
plasma
estim
halflif
h
gener
clinic
trial
carri
thu
far
conclud
well
toler
major
dose
schedul
studi
evid
target
inhibit
antitumour
activ
support
continu
investig
alon
combin
strategi
potenti
treatment
varieti
human
cancer
nawrocki
et
al
zhao
et
al
due
implic
dub
regul
crucial
signal
pathway
fig
surpris
deregul
involv
grow
number
diseas
includ
neurolog
disord
viral
infect
cancer
inde
member
dub
famili
known
contribut
neoplast
transform
fanconi
anaemia
prostat
cancer
breast
cancer
adenocarcinoma
prostat
cancer
nonsmallcel
lung
adenocarcinoma
leukaemia
myeloma
breast
cancer
edelmann
et
al
hussain
et
al
genet
alter
dub
cyld
associ
skin
bone
marrow
tumour
progress
respect
final
alter
express
bcell
tcell
lymphoma
carcinoma
brain
lung
testicular
cancer
observ
cancer
hussain
et
al
nicholson
et
al
sippl
et
al
high
degre
substrat
specif
well
defin
catalyt
pocket
make
dub
druggabl
amen
screen
librari
small
molecul
eletr
wilkinson
work
carri
last
year
led
identif
inhibitor
select
action
variou
usp
target
demonstr
feasibl
select
target
dub
gener
initi
hit
obtain
high
throughput
screen
ht
compound
librari
follow
optim
use
structureact
relationship
kramer
et
al
compani
like
novarti
progenra
hybrigen
patent
compound
inhibit
distinct
dub
see
tabl
present
follow
section
howev
best
knowledg
yet
enter
clinic
trial
recent
ht
approach
led
identif
two
potent
select
revers
inhibitor
enzymat
activ
complex
pimozid
one
bestcharacter
dub
regul
sever
import
step
dna
damag
respons
mainli
fanconi
anaemia
fa
hereditari
disord
character
congenit
abnorm
progress
bone
marrow
failur
hypersensit
dna
crosslink
agent
genom
instabl
increas
suscept
cancer
li
et
al
reyesturcu
et
al
frequent
overexpress
tumour
like
cervic
gastric
cancer
melanoma
sarcoma
importantli
inhibitor
act
synergist
chemotherapi
drug
cisplatin
inhibit
prolifer
cisplatinresist
nonsmal
cell
lung
cancer
nsclc
cell
chen
et
al
garciasantisteban
et
al
one
compani
hybrigen
develop
varieti
differ
inhibitor
usp
famili
tabl
exampl
cyanoindenopyrazin
deriv
small
molecul
compound
modul
catalyt
reaction
colland
et
al
also
known
herp
virusassoci
usp
hausp
critic
cancer
progress
destabil
effect
tumour
suppressor
cheon
baek
cummin
vogelstein
howev
also
modifi
substrat
claspin
pten
suggest
exert
independ
effect
control
cell
prolifer
apoptosi
faustrup
et
al
song
et
al
van
der
horst
et
al
treatment
stabil
activ
transcript
gene
without
induc
genotox
stress
inhibit
cancer
cell
growth
anoth
compound
recent
develop
hybrigen
secondgener
irrevers
inhibitor
specif
capabl
regul
substrat
cancer
cell
recapitul
knockdown
phenotyp
reverdi
et
al
recent
independ
screen
perform
progenra
also
identifi
compound
analogu
inhibitor
capabl
induc
apoptosi
multipl
myeloma
cell
resist
convent
bortezomib
therapi
chauhan
et
al
anoth
ht
identifi
select
revers
smallmolecul
inhibitor
human
togeth
dub
associ
proteasom
bind
specif
activ
form
enhanc
degrad
sever
protein
involv
neurodegen
diseas
like
tau
suggest
potenti
strategi
reduc
level
misfold
aggreg
protein
cell
proteotox
stress
lee
et
al
todi
paulson
inhibitor
dub
also
use
antivir
drug
develop
sinc
virus
also
encod
dub
exampl
mention
also
abl
inhibit
replic
dengu
viru
nag
finley
case
sever
acut
respiratori
syndrom
sar
caus
sarscoronaviru
dub
call
papainlik
proteas
plpro
block
antivir
respons
edelmann
et
al
mielech
et
al
noncoval
inhibitor
plpro
synthes
inhibitor
modifi
conform
plpro
induc
inhibit
catalyt
activ
select
block
sarscoronaviru
viral
replic
without
measur
cytotox
effect
ratia
et
al
look
effect
therapeut
sever
acut
sar
found
specif
inhibitor
plpro
potenti
use
cellular
dub
inhibitor
studi
best
dock
score
bind
energi
chen
et
al
chou
et
al
recent
pimozid
identifi
potent
inhibitor
chen
et
al
pimozid
antipsychot
drug
also
known
neurolept
properti
treatment
patient
schizophrenia
opler
feinberg
tourett
syndrom
resist
tic
addit
pimozid
inhibit
prolifer
human
melanoma
breast
cancer
cell
neifeld
et
al
strobl
abl
revers
chemo
resist
nonsmal
cell
lung
cancer
cell
dna
crosslink
cisplatin
support
potenti
target
novel
anticanc
therapi
chen
et
al
tabl
antimetabolit
antineoplast
agent
immunosuppress
properti
interf
nucleic
acid
synthesi
inhibit
purin
metabol
antimetabolit
also
describ
plpro
potenti
inhibitor
usual
use
combin
drug
treatment
remissionmainten
program
leukaemia
sever
clinic
trial
establish
current
progress
use
trial
list
wwwclinicaltrialgov
trial
list
wwwclinicaltrialgov
combin
chemotherapeut
drug
treatment
leukaemia
brain
tumour
breast
ovarian
cancer
well
immun
diseas
tumour
protein
involv
broad
rang
critic
pathway
cell
cycl
apoptosi
senesc
dna
repair
metabol
develop
innat
immun
vousden
prive
monitor
integr
genom
tightli
regul
differ
intracellular
pathway
main
regul
ubiquitin
ligas
mous
involv
autoregulatori
loop
control
stabil
activ
transcript
factor
found
mutat
andor
deregul
half
known
cancer
soussi
beroud
case
remain
function
abnorm
retain
overexpress
mutat
homologu
highresolut
crystal
structur
publish
kussi
et
al
recent
crystal
structur
resolv
popowicz
et
al
studi
nonpeptid
small
molecul
inhibitor
design
specif
target
hydrophob
pocket
includ
three
trivial
amino
acid
common
mdmx
hoffmannla
roch
first
compani
develop
one
potent
inhibitor
name
nutlin
three
gener
nutlin
gener
aim
improv
stabil
affin
bioavail
inhibitor
optim
first
inhibitor
use
clinic
trial
treat
multipl
human
cancer
tovar
et
al
compani
like
amgen
develop
seri
optim
compound
piperidinon
class
compound
obtain
effici
inhibit
tumour
regress
rew
et
al
sinc
amgen
also
develop
inhibitor
contain
morpholinon
core
signific
increas
potenc
metabol
stabil
compar
piperidinon
seri
emerg
inhibitor
remark
biochem
potenc
pharmacokinet
properti
gonzalez
et
al
tabl
develop
aileron
therapeut
first
highli
potent
select
stapl
peptid
function
dual
inhibitor
mdmx
bind
mdmx
nanomolar
affin
restor
activ
chang
et
al
potenti
use
treatment
solid
tumour
cancer
like
aml
cml
breast
cancer
liposarcoma
melanoma
colon
cancer
stapl
peptid
emerg
promis
new
modal
wide
rang
therapeut
target
base
roch
ascenta
tdp
johnson
johnson
structur
use
nmr
spectroscopi
approach
silico
compoundselect
process
priaxon
ag
develop
two
new
class
inhibitor
test
cellular
cultur
inhibit
prolifer
assay
preclin
trial
cheok
et
al
addit
inhibitor
inhibitor
ubiquitin
ligas
also
clinic
trial
progenra
develop
compound
capabl
specif
inhibit
ubiquitin
ligas
ligas
associ
muscl
wast
diseas
specif
inhibit
autoubiquityl
activ
without
affect
ubiquitin
enzym
result
stabil
muscl
protein
product
preclin
develop
sinc
aim
provid
novel
therapeut
strategi
protect
muscl
sarcopenia
age
atrophi
associ
common
diseas
cancer
aid
congest
heart
diseas
sever
burn
eddin
et
al
tabl
progenra
also
develop
inhibitor
treatment
rheumatoid
arthriti
ra
synoviolin
ring
ubiquitin
ligas
implic
endoplasm
reticulumassoci
degrad
erad
pathway
synoviolin
highli
express
rheumatoid
synovi
cell
possibl
involv
pathogenesi
ra
use
ht
two
class
small
molecul
identifi
effici
inhibit
synoviolin
activ
inhibit
autoubiquitin
enzymat
activ
thu
block
prolifer
synovi
cell
inhibitor
preclin
develop
sinc
yagishita
et
al
highrisk
oncogen
human
papillomaviru
hpv
type
includ
hpv
hpv
associ
cervic
cancer
oncoprotein
critic
factor
maintain
malign
phenotyp
hpv
tumour
cell
use
yeast
twohybrid
screen
cancer
therapeut
crc
develop
linear
short
peptid
specif
bind
high
affin
oncoprotein
affect
interact
ubiquitin
ligas
also
known
degrad
restor
intracellular
use
short
peptid
new
strategi
treatment
hpv
cancer
inhibitor
preclin
stage
studi
sinc
dymalla
et
al
ubiquitin
ligas
cblb
key
regul
activ
threshold
matur
lymphocyt
immunolog
toler
autoimmun
apeiron
biolog
develop
specif
cblb
ligas
inhibitor
stimul
immun
cell
provid
novel
way
treat
cancer
effect
compound
preclin
develop
sinc
wwwclinicaltrialsgov
siah
seven
absentia
homologu
famili
ubiquitin
ligas
regul
cellular
event
critic
cancer
develop
progress
cancer
therapeut
develop
coval
peptidesbas
inhibitor
cystrap
moieti
disrupt
siah
interact
adaptor
protein
therebi
block
cancer
progress
small
molecul
siah
inhibitor
current
test
preclin
phase
patient
breast
ovarian
prostat
pancrea
cancer
stebbin
et
al
experi
ubiquitin
inhibitor
clinic
trial
limit
compar
proteasom
inhibitor
mani
phase
clinic
develop
primari
outcom
maximum
toler
dose
doselimit
toxic
safeti
current
evalu
subsequ
efficaci
pharmacokinet
pharmacodynam
measur
secondari
outcom
gener
first
inhibitor
hoffmannla
roch
develop
anoth
inhibitor
whose
structur
publish
oral
avail
inhibitor
phase
clinic
trial
sinc
propos
cancer
patient
solid
tumour
acut
myelogen
advanc
malign
except
case
leukaemia
howev
respect
latter
includ
anoth
trial
combin
cytarabin
chemotherapeut
agent
use
treatment
leukaemia
nonhodgkin
lymphoma
third
trial
consider
use
associ
cytarabin
anthracyclin
small
analogu
molecul
small
molecul
inhibitor
develop
ascenta
therapeut
sanofi
current
phase
clinic
trial
sinc
either
alon
clinic
trial
combin
pimasertib
clinic
trial
oral
drug
may
use
patient
malign
neoplasm
shen
et
al
oral
inhibitor
develop
novarti
treatment
cancer
advanc
solid
tumour
patient
regress
despit
standard
therapi
standard
therapi
exist
cell
exhibit
wild
type
respond
drug
phase
clinic
trial
sinc
merck
develop
inhibitor
includ
phase
clinic
trial
patient
advanc
solid
tumour
treatment
avail
recurr
acut
myelogen
leukaemia
liposarcoma
like
also
evalu
phase
clinic
trial
combin
cytarabin
oral
inhibitor
develop
sankyo
treat
patient
advanc
solid
tumour
lymphoma
exhibit
mutat
wt
descript
molecul
yet
publish
alreadi
includ
phase
clinic
trial
even
first
piec
puzzl
atpdepend
pathway
discov
year
ago
everi
year
new
compon
regulatori
mechan
control
system
describ
despit
brief
didact
view
up
classifi
enzym
cofactor
substrat
system
lot
complex
present
still
distinct
lack
knowledg
respect
overal
organ
instanc
well
known
certain
circumst
sever
modifyingdemodifi
enzym
act
distinct
member
ubiquitin
famili
leideck
et
al
proteasom
subunit
substrat
ubiquitin
ubiquitinlik
molecul
cui
et
al
proteasom
also
drive
proteolysi
absenc
protein
modif
eral
coffino
although
function
outcom
recent
find
complet
understood
becom
clear
simpli
target
singl
enzymesubstr
pair
difficult
howev
stop
use
inhibitor
treat
distinct
patholog
recent
occur
proteasom
inhibitor
block
multipl
process
sinc
discoveri
drug
act
differ
level
also
increas
chanc
clinic
success
furthermor
experi
use
combin
differ
inhibitor
quit
posit
case
patient
respond
resist
current
treatment
although
combinatori
drug
therapi
might
appear
contradict
initi
aim
reduc
undesir
side
effect
possibl
eventu
could
effect
compromis
efficaci
cytotox
better
defin
pharmacodynam
pharmacokinet
studi
final
although
describ
use
up
inhibitor
treat
cancer
mani
also
use
treat
quit
divers
diseas
cardiac
immun
neurodegen
disord
use
chemic
inhibitor
contribut
better
understand
multipl
cellular
pathway
regul
up
importantli
inhibitor
open
new
perspect
treatment
variou
diseas
case
bortezomibvelcad
review
xolalpa
et
al
